AZD8848 Single Ascending Dose Study

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: March 20, 2012
Last updated: August 4, 2014
Last verified: August 2014
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.

Condition Intervention Phase
Drug: AZD8848
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of adverse events [ Time Frame: Screening up to Month 11 - 13 ] [ Designated as safety issue: Yes ]
  • Changes in baseline of vital signs (blood pressure and pulse), clinical laboratory tests, ECGs,spirometry and physical examination findings will be presented [ Time Frame: Screening up to Day 13 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic profile for AZD8848 and AZ12432045 combined (measured as total AZ12432045) and, if possible, for AZD8848 alone after inhaled administration of AZD8848. Parameters include AUC, Cmax, tmax, lamda z, t1/2lamda z, AUC (0-t), CL/F and Vz/F [ Time Frame: On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h ] [ Designated as safety issue: No ]
  • Pharmacodynamic effect of AZD8848 after inhaled administration by measuring CXCL10 concentration and change-from-baseline ratios in blood and induced sputum [ Time Frame: Between Day -5 and Day -2, at 3 timepoints on Day 1 - Day 3 and on Day 13 ] [ Designated as safety issue: No ]

Enrollment: 55
Study Start Date: April 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD8848 Drug: AZD8848
Single dose, oral inhalation (nebuliser solution)
Placebo Comparator: Placebo Drug: Placebo
Single dose, oral inhalation (nebuliser solution)

Detailed Description:
A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy men or women aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
  • Women can be of childbearing potential and must have been stable on a highly effective contraceptive method for at least 3 months prior to Visit 1 (screening) and be willing to continue on the chosen contraceptive method
  • Male subjects should be willing to use a condom (with spermicide) to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm or fathering a child from the day of the investigational product administration until 3 months
  • Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
  • Ability to produce sputum of good enough quality for assessment of biomarkers

Exclusion Criteria:

  • Abnormal vital signs, after 10 minutes supine rest, defined as any of the following (SBP > 140 mmHg, Diastolic blood pressure (DBP) > 90 mmHg, Heart rate < 40 or > 85 beats per minute)
  • Prolonged QTcF > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome
  • History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class as AZD8848
  • History of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT syndrome, or sudden death)
  • History of asthma or allergic rhinitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01560234

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Study Director: Aray Aggarwal AstraZeneca R&D, 35 Gathouse Drive, Ma 02451 USA
Principal Investigator: James Ritter, BA,MA D Phil,BM BCh,MRCP,FRCP Quintile Drug Research Unit at Guy's Hospital Quintiles Ltd 6 Newcomen Street London SE1 1YR United Kingdom
  More Information

Responsible Party: AstraZeneca Identifier: NCT01560234     History of Changes
Other Study ID Numbers: D0542C00001  Eudract number 2011-005986-20 
Study First Received: March 20, 2012
Last Updated: August 4, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
inhaled processed this record on May 26, 2016